Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 8/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.30 |
| ▸ | ITGAV | P06756 | 1/20 | 0.30 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.30 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.30 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.30 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2191541 | 0.86 | CRHR1 (0.34) | CRHR1ALOX15 | |
| SCHEMBL13271926 | 0.73 | ALOX15 (0.36) | ALDH1A1KDM4ELMNAALOX15 | |
| SCHEMBL2191694 | 0.67 | SMN1; SMN2 (0.43) | ALDH1A1KDM4ELMNAALOX15RAB9A | |
| SCHEMBL15219419 | 0.67 | CCNC (0.41) | CRHR1TDO2 | |
| SCHEMBL12146457 | 0.66 | CRHR1 (0.40) | CRHR1ALDH1A1POLBTDO2 | |
| SCHEMBL11915934 | 0.64 | CRHR1 (0.38) | CRHR1TDO2 | |
| SCHEMBL2194328 | 0.60 | HTT (0.41) | ALDH1A1KDM4ELMNAALOX15RAB9A | |
| SCHEMBL2258351 | 0.59 | CRHR1 (0.42) | CRHR1 | |
| SCHEMBL13493779 | 0.59 | CRHR1 (0.52) | CRHR1 | |
| SCHEMBL2331351 | 0.58 | CRHR1 (0.41) | CRHR1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172255-A1 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists | SB PHARMCO PUERTO RICO INC | 2011-07-14 | — | — | US | claimed |
| US-20110172255-A1 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists | SB PHARMCO PUERTO RICO INC | 2011-07-14 | — | — | US | disclosed |
| US-20110172255-A1 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists | SB PHARMCO PUERTO RICO INC | 2011-07-14 | — | — | US | disclosed |
| US-20110172255-A1 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists | SB PHARMCO PUERTO RICO INC | 2011-07-14 | — | — | US | disclosed |
| EP-1611133-B1 | CONDENSED N-HETEROCYCLIC COMPOUND AND USE THEREOFF AS CRF RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORK LTD (IE) | 2010-07-07 | — | — | EP | disclosed |
| EP-1618107-B1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORK LTD (IE) | 2010-06-30 | — | — | EP | disclosed |
| EP-2186813-A1 | Condensed N-heterocyclic compounds and their use as CRF receptor antagonists | SmithKline Beecham (Cork) Limited (IE) | 2010-05-19 | — | — | EP | disclosed |
| US-7427630-B2 | Condensed N-heterocyclic compounds and their use as CRF receptor antagonists | SB PHARMACO PUERTO RICO INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427630-B2 | Condensed N-heterocyclic compounds and their use as CRF receptor antagonists | SB PHARMACO PUERTO RICO INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427630-B2 | Condensed N-heterocyclic compounds and their use as CRF receptor antagonists | SB PHARMACO PUERTO RICO INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070021429-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2007-01-25 | — | — | US | disclosed |
| US-20070004708-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | NEUROCRINE BIOSCIENCES, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004708-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | NEUROCRINE BIOSCIENCES, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004708-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | NEUROCRINE BIOSCIENCES, INC. | 2007-01-04 | — | — | US | disclosed |
| EP-1618107-A1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SB Pharmco Puerto Rico Inc (US) | 2006-01-25 | — | — | EP | disclosed |
| WO-2004094419-A1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SB PHARMCO PUERTO RICO INC (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172255-A1 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists | CRH, CRHR1, CRHR2 | CRHR1 2/4885ALDH1A1 3090/4885KDM4E 4412/4885 |
| US-20070021429-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | CRHR1, NR3C2, CRHR2 | CRHR1 1/4885ALDH1A1 3578/4885KDM4E 3605/4885 |
| US-20070004708-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | CRHR2, NR3C2, CRHR1 | CRHR1 3/4885ALDH1A1 4153/4885KDM4E 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.